Close Menu
    Facebook X (Twitter) Instagram
    SciTechDaily
    • Biology
    • Chemistry
    • Earth
    • Health
    • Physics
    • Science
    • Space
    • Technology
    Facebook X (Twitter) Pinterest YouTube RSS
    SciTechDaily
    Home»Health»New FDA-Approved Pill Lowers High Blood Pressure and May Slow Kidney Disease
    Health

    New FDA-Approved Pill Lowers High Blood Pressure and May Slow Kidney Disease

    By SciTechDaily.comNovember 19, 2026No Comments7 Mins Read
    Facebook Twitter Pinterest Telegram LinkedIn WhatsApp Email Reddit
    Share
    Facebook Twitter LinkedIn Pinterest Telegram Email Reddit
    Measurement of Blood Pressure Heart Cardiology
    A newly approved blood pressure drug is showing promise beyond treating hypertension, with early research suggesting potential benefits for kidney health. Credit: Shutterstock

    A new drug targeting a hormone linked to hypertension has shown encouraging results in patients with chronic kidney disease.

    A drug that showed early signs of protecting damaged kidneys has now received FDA approval for treating high blood pressure that remains uncontrolled despite medication. Called Baxfendy (baxdrostat), the treatment targets a hormone involved in both hypertension and kidney disease.

    The approval follows Phase 3 clinical trials showing substantial blood pressure reductions. Earlier research also found that baxdrostat lowered a key marker of kidney damage by 55%, suggesting potential benefits beyond hypertension. Whether the medication can slow kidney disease progression remains under investigation.

    FDA Approval Backed by Strong Clinical Trial Results

    The FDA approved AstraZeneca’s Baxfendy in May 2026 for adults whose hypertension remains inadequately controlled by existing treatments. It is the first approved aldosterone synthase inhibitor, a class of drugs that reduces production of the hormone aldosterone.

    In the Phase 3 BaxHTN trial involving 796 patients, the 2 mg dose reduced systolic blood pressure by an average of 15.7 mm Hg after 12 weeks, compared with 5.8 mm Hg for placebo. The additional reduction of 9.8 mm Hg was statistically significant. A lower 1 mg dose also produced meaningful improvements.

    Dr. Bryan Williams, Chair of Medicine at University College London and the trial’s primary investigator, said: “We have been waiting for an innovative medication like Baxfendy for hypertension for many years. Its novel way of lowering blood pressure has the potential to transform clinical practice by targeting a root cause of persistently uncontrolled hypertension. In addition, the nearly double-digit placebo-adjusted systolic blood pressure reduction achieved with Baxfendy is exciting and clinically meaningful for clinicians and patients. Epidemiological data indicate that a 10 mmHg decrease in systolic blood pressure is associated with a roughly 20% lower risk of serious cardiovascular events.”

    How the Drug Targets a Major Cause of Hypertension

    Aldosterone regulates sodium and water balance in the body. Excessive levels cause the kidneys to retain fluid, increasing blood pressure and potentially contributing to kidney inflammation and scarring.

    Baxdrostat inhibits the enzyme responsible for producing aldosterone rather than blocking the hormone’s receptors, as some existing medications do. This approach may benefit patients whose blood pressure remains high despite multiple treatments.

    A separate Phase 3 trial, Bax24, involving 218 patients found that baxdrostat lowered average systolic blood pressure over 24 hours by 14.0 mm Hg more than placebo. The effect persisted throughout the day and night, according to findings published in The Lancet.

    Earlier Study Finds Potential Kidney Benefits

    High blood pressure and chronic kidney disease can worsen each other. Elevated pressure damages the kidneys’ filtering structures, while declining kidney function makes hypertension harder to control.

    “These findings are encouraging for people living with chronic kidney disease and high blood pressure, two conditions that often go hand-in-hand and create a dangerous cycle,” said lead study author Jamie P. Dwyer, M.D., a professor of medicine at University of Utah Health. “High blood pressure can worsen kidney function and declining kidney function can further elevate blood pressure, and these outcomes can be life-altering for patients.”

    In the Phase 2 FigHTN trial, 192 patients with chronic kidney disease and uncontrolled hypertension were randomly assigned to receive baxdrostat or placebo alongside standard treatment. After 26 weeks, systolic blood pressure fell an average of 8.1 mm Hg more in the baxdrostat groups.

    Researchers also measured urinary albumin, a protein associated with kidney damage when present in elevated amounts. Levels were 55% lower in patients receiving baxdrostat than in those taking placebo. The findings were published in the Journal of the American Society of Nephrology.

    Safety Concerns and Remaining Questions

    The earlier kidney disease trial found elevated blood potassium in 41% of baxdrostat recipients, compared with 5% of placebo recipients. Most cases were mild or moderate, but excessive potassium can cause dangerous heart rhythm disturbances. Serious adverse events occurred in 9% and 3% of participants, respectively.

    Although subsequent Phase 3 hypertension studies reported no unexpected safety findings, potassium levels and kidney function require monitoring during treatment.

    “The reduction in urine albumin gives us hope that baxdrostat may also help delay kidney damage. This potential is now being tested in two large Phase 3 trials to determine if baxdrostat delays the progression of kidney disease,” said Dwyer.

    Larger studies are investigating whether baxdrostat can preserve kidney function over time, including trials combining it with dapagliflozin, an established kidney-protective medication. Its FDA approval currently covers hypertension, not the prevention of kidney disease progression.

    “These new findings are reassuring that this new class of antihypertensive medications are likely to have both kidney- and cardio-protective benefits and to be safe and effective for broad patient populations,” said Jordana B. Cohen, M.D., M.S.C.E., immediate past chair of the American Heart Association’s Hypertension and Kidney Cardiovascular Science Committee. “Patients with chronic kidney disease were historically often excluded from drug studies. It is particularly reassuring to know that patients with chronic kidney disease, who have very high rates of hypertension and elevated renin-angiotensin aldosterone activity, were represented in their own study, tolerated the medication well, and had both blood pressure and albuminuric benefits. This medication class could be a game changer in the management of hypertension in this patient group.”

    References:

    “Efficacy and Safety of Baxdrostat in Participants with CKD and Uncontrolled Hypertension: A Randomized, Double-Blind, Placebo-Controlled Trial” by Jamie P. Dwyer, Noha Maklad, Ola Vedin, John Monyak, Robin Myte, Glenn M. Chertow, Hiddo J.L. Heerspink and Dustin J. Little, 6 September 2025, Journal of the American Society of Nephrology.
    DOI: 10.1681/ASN.0000000849

    “Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial” by Michel Azizi, Jenifer M Brown, Jamie P Dwyer, John M Flack, Erica S W Jones, Raisa Kurlyandskaya, Hongjian Li, Filip Birve, Aina S Lihn, Shira Perl, Markus P Schlaich, Hirotaka Shibata, Ji-Guang Wang, Bryan Williams, Cesar Zaidman, Sonia Sassone, Miguel Cuenca, Diego Arakaki, Mariano Chahin, María Andrea Steinacher, Fredy Ferre Pacora, Juan Loureyro, Jun Yang, Markus Schlaich, Tine De Backer, Hans T Kindt, Philippe Delmotte, Blagovest Stoimenov, Kiril Dzhomanov, Krassimir Cvetkov, Dimitar Raev, Stefan Naydenov, Shivinder Jolly, John Vyselaar, Luis Noronha, Daniel Gaudet, Amritanshu Pandey, Jennifer Ringrose, Yves Robitaille, Jiri Vesely, Jiri Krupicka, Ladislav Busak, Jitka Pruchova, Wolfgang Jungmair, Sebastian Cremer, Markus van der Giet, Stephan Schirmer, Spasija Parizova, Michael Doumas, George Stergiou, Konstantinos Tsioufis, Zoltán Miklós Járai, András Vorobcsuk, Tibor Kiss, Gizella Pap, András Csaba Nagy, Attila Farkas, Desmond Samuel, Mohd Faiz Faizul Fauzi, Mohamad Muslim Jamian, Louie Tirador, Gabriel Jocson, Marek Rajzer, Andrzej Januszewicz, Andrzej Tykarski, Michał Hoffmann, Jan Zbigniew Peruga, Edyta Zbroch, Piotr Sobieraj, Abdulmajid Mukhtar, Talal AlJabbary, Lubomir Antalik, Jan Fedacko, Peter Fulop, Lesley Burgess, Gulam Latiff, Julián Segura de la Morena, José Antonio García Donaire, Miguel Camafort Babkowski, Alejandro de la Sierra, Javier Sobrino Martínez, Anna Oliveras Serrano, Fernando Martinez, Manuel Gorostidi Pérez, Francisco Fuentes Jimenez, Chern-En Chiang, Kang-Ling Wang, Yen-Wen Wu, I-Chang Hsieh, Praew Kotruchin, Yongkasem Vorasettakarnkij, Weranuj Roubsanthisuk, Prin Vathesatogkit, Krit Leemasawat, Hilmi Erdem Sumbul, Özge Turgay Yıldırım, Cagri Yayla, Ozkan Gungor, Ismail Kocyigit, Auditi Naziat, Manish Saxena, Gordon Irvine, Andrew Hill, Amardeep Heer, David Wingfield, Sam Davies, John Jackson, Philip Lewis, David Bernard, Minesh Rajpal, Christopher Romero, Kianoosh Kaveh, Mario Guillen, Lorena Lewy-Alterbaum, Vanna Gold, Travis Taylor, Justin Arambasick, John Ducker, Rekha John, Eric Kirk, Manuel Montero, Nauman Shahid, George Thomas, Gary Sirken, David Guzman, Hai Nguyen, Dung Pham, Hai Nguyen, Hien Nguyen, Thao Dinh and Yen Nguyen, 7 March 2026, The Lancet.
    DOI: 10.1016/S0140-6736(25)02549-8

    Never miss a breakthrough: Join the SciTechDaily newsletter.
    Follow us on Google and Google News.

    American Heart Association Blood Pressure Cardiology Hypertension Kidney
    Share. Facebook Twitter Pinterest LinkedIn Email Reddit

    Related Articles

    New Pill Lowers Stubborn Blood Pressure and Protects the Kidneys

    New Pill Lowers Stubborn Blood Pressure and May Slow Kidney Disease

    Hidden Hypertension Hazard: Just a Single Alcoholic Drink a Day May Raise Blood Pressure

    Oral Estrogen Hormone Therapy’s Troubling Tie to High Blood Pressure

    New Research Reveals Optimal Dose of Omega-3 Fatty Acids To Lower Blood Pressure

    Eating Protein From a Greater Variety of Sources Linked With Lower Risk of High Blood Pressure

    Easy 5-Minute Workout Lowers Blood Pressure As Much as Exercise or Medication

    Blood Pressure-Lowering Medications Linked to Less Memory Decline in Older Adults

    New Research Shows Cannabis Reduces Blood Pressure in Older Adults With Hypertension

    Leave A Reply Cancel Reply

    • Facebook
    • Twitter
    • Pinterest
    • YouTube

    Don't Miss a Discovery

    Subscribe for the Latest in Science & Tech!

    Trending News

    Scientists Discover Two Monster Black Holes at the Dawn of Time That Shouldn’t Exist

    Not All Physical Activity Protects Your Brain, Scientists Warn

    Rewriting History: New Research Reveals Ancient Iron Age King May Have Been a Woman

    A Strange Black Hole Gap Could Reveal Stars That Died Without Exploding

    A Deadly Blood Cancer May Begin More Than 50 Years Before Symptoms Appear

    Scientists Discover a Giant 66-Pound Rodent That Lived 34 Million Years Ago

    Scientists Unlock a New Way To Photograph Events That Vanish in Trillionths of a Second

    Why Do We Feel Colder As We Get Older? New Study Uncovers a Hidden Mechanism

    Follow SciTechDaily
    • Facebook
    • Twitter
    • YouTube
    • Pinterest
    • Newsletter
    • RSS
    SciTech News
    • Biology News
    • Chemistry News
    • Earth News
    • Health News
    • Physics News
    • Science News
    • Space News
    • Technology News
    Recent Posts
    • New FDA-Approved Pill Lowers High Blood Pressure and May Slow Kidney Disease
    • Why Sleeping 9 Hours After 50 May Be a Warning Sign for Your Career
    • Experimental Drug Wipes Out Aggressive Pancreatic Cancer in 75% of Mice and Triggers Lasting Immunity
    • Scientists Solve a Longstanding Mystery About the Tiny Gateways That Protect Our DNA
    • Scientists Just Challenged a Decades-Old Belief About How Cells Work
    Copyright © 1998 - 2026 SciTechDaily. All Rights Reserved.
    • Science News
    • About
    • Contact
    • Editorial Board
    • Privacy Policy
    • Terms of Use

    Type above and press Enter to search. Press Esc to cancel.